Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Completes Agilent Microarray Service Certification

NEW YORK, Oct. 28 (GenomeWeb News) - Paradigm Genetics and Agilent Technologies said today that Paradigm is the first company to be certified under Agilent's certified microarray service provider program.

The certification builds on a research service relationship that the companies entered in March.

To be eligible for certification, Agilent said that service laboratories must accurately analyze 60-mer microarrays on the complete Agilent gene expression platform, which includes a microarray scanner, hybridization and labeling kits, feature extraction software, and a Rosetta gene expression data analysis system.

The certification "constitutes a formal endorsement from Agilent that we can and continue to provide reliable microarray results that researchers can count on from sample to sample, study to study," said Heinrich Gugger, president and CEO of Paradigm.

Last week, Paradigm announced that it would also provide microarray processing services for the Affymetrix GeneChip platform.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.